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Results
hAFSC Phenotype and Karyotype before Injection
hAFSC, before injection, present a fibroblastoid shape as shown
in Figure 1A. The cells were then tested to confirm a normal
karyotype before in vivo applications, to exclude chromosomal
abnormalities that could compromise their pluripotential capabil-
ity (Figure 1B). hAFSC were analyzed for the expression of early
and late kidney markers before injection. As shown in Figure 1C,
prior to injection, hAFSC were negative for the most important
kidney markers, ranging from transcription factors expressed
during early kidney development to late differentiation markers.
Thus, we confirmed that hAFSC are not specifically committed to
kidney progenitor cells when cultured in vitro.
Evaluation of the Glycerol Induced Muscle Damage and
ATN Using Period Acid Schiff Staining (PAS) and TUNEL
Staining
Figure 2A demonstrates normal morphology of a nu/nu mouse
kidney before any damage; the proximal and distal tubules are
intact as well as the glomeruli. Figure 2B shows morphology of
the kidney 3 days after intramuscular injection of glycerol. Marked
disorganization of the normal structure of proximal and distal
tubules is evident, with cast formation and brush border
disruption, while most of the glomeruli remain intact. This type
of damage is typical of ATN injury induced by rhabdomyolysis,
where the main structures of the kidneys that undergo damage are
tubules and not glomeruli. Figure 2D shows an increase in
apoptotic cells (TUNEL staining), 72 hours after damage
induction as compared with the control that did not undergo
glycerol induced muscle damage (Figure 2C). The difference in
the number of apoptotic cells present in the glycerol treated mice
when compared with the untreated control mice was highly
statistically significant (P,0.01) (Figure 2E).
In Vivo Detection of hAFSC by Bioluminescence
hAFSC, transduced with a lentivirus coding for luciferase,
showed stable expression of the transgene over many population
doublings. The cells not infected with the lentivirus and exposed to
luciferin (the luciferase substate) did not reveal any biolumines-
cence, while the transfected cells exposed to luciferin continue to
express the bioluminescent signal after 20 population doublings
(Figure 3A).
In Figure 3B is shown an in vitro experiment to determine the
minimal number (16105) of cells that exhibited a readily
detectable optical signal. In Figure 3C is shown live imaging of
a right kidney injected with 1,26106 hAFSC after damage
induction. The animal injected with luciferin only (as a negative
control) did not show any signal (panel 1), while the lucierase
fluorescent signal is clearly evident, and even spreads into multiple
zones of the body, such as the lung over the first few hours
(panels 2–3). The signal for hAFSC in the area of the kidney can
be seen at 24 hours after injection (panel 4), was strongest at 48
hours and 72 hours, and persisted for up to 6 days (panels 5–6),
after which the signal began to diminish over the next several days
(panel 7–8). However, 21 days after injection, the signal was still
evident in the area of the kidney (panel 9). Animals were
sacrificed at 21 days after injections of hAFSC and DNA
Figure 1. hAFSC morphology, gene expression and karyotype. A. Morphology of hAFSC population. After 40 passages in culture under
bright field the cells present a fibroblastoid appearance (106). B. Karyotype of hAFSC after 38 passages. C. RT-PCR of hAFSC before in vivo injection.
Neither early nor mature kidney markers are expressed. hACTB is used as a housekeeping gene.
doi:10.1371/journal.pone.0009357.g001
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extraction and PCR were performed on injected and non-injected
kidneys in order to determine the presence of luciferase gene. Both
the luciferase gene and a human housekeeping gene ACTB (both
expressed only in human cells) were present only in the injected
kidney tissue, as confirmed by the absence of the both
housekeeping ACTB and luciferase gene in non-injected kidneys
(Figure 3D). In addition, the presence of hAFSC in the injected
kidneys was also confirmed by positive immunostaining against
luciferase, as shown in Figure 3E.
Detection of hAFSC in Damaged Kidneys by
Immunohistochemistry and Gene Expression
The presence of injected hAFSC was evaluated histologically.
Frozen sections performed at 1 week after injection confirmed
the presence of hAFSC, as detected by red fluorescence of the
surface marker CM-DiI (Figure 4A). We further observed
several instances where the CM-Dil signal from the hAFSC
overlapped with the fluorescent-staining of a kidney markers such
as Peanut Agglutinin as well as Dolichus Biflorus Agglutinin at 3
weeks after injection; indicating that hAFSC are able to
differentiate into cells expressing both adult proximal and distal
tubular agglutinins (Figure 4B,C). In some rare cases hAFSC
were also found in glomerular structures expressing Glial Derived
Neurotrophic Factor (GDNF), as identified by a specific antibody
reacting against human GDNF, indicating that the stem cells
were also able to express early glomerular markers of differen-
tiation (Figure 4D). In Figure 4E, where the cells were not
labeled with the CM-Dil, hAFSC were identified with green
fluorescence positive for the luciferase staining, and these
injected cells also double stained for Aquaporin 2. After 21 days,
RT-PCR was performed using human specific primers on the
harvested kidneys, and the expression of several human specific
kidney genes (early as well as late markers of differentiation) by
the hAFSC in the injected kidneys were identified. Injected
hAFSC expressed NPHS1, AQP2, PAX2, and OCLN, when
compared to hAFSC before injection (Figure 4F). In
Figure 4G demonstrates that the human specific primers did
not cross react with mouse kidney sequences.
Kidney Physiology: Serum Creatinine and Blood Urea
Nitrogen (BUN) Measurements
A control group of 10 nu/nu mice was used to determine basal
level of serum creatinine and blood urea nitrogen (BUN) in normal
nu/nu mice, which averaged 0.6 mg/dl and 27 mg/dl, respective-
Figure 2. Morphological analysis of glycerol-rhabodomyolysis-induced-ATN model in nu/nu mice. A. Histological section showing PAS
staining of a nu/nu mouse kidney. Proximal and distal tubules and glomeruli, as indicated by the arrows, present normal morphology (40x). B.
Histological section showing PAS staining of a nu/nu mouse kidney after 3 days of glycerol-rhabdomyolysis-induced ATN. Destruction of brush
borders, intraluminal cast formation as well as general disorganization of the kidney structures is evident (arrow, 40x) C. TUNEL staining of a nu/nu
mouse kidney. The level of apoptotic cells is very low, when compared with TUNEL staining of a nu/nu mouse kidney after 3 days of glycerol-induced
ATN (D), (10x). E. Graph showing the effect of glycerol ATN on kidney cell apoptosis (number of positive apoptotic nuclei per 300 nuclei) compared
with untreated controls. Values are presented as mean 6 SEM (*** p, 0.001).
doi:10.1371/journal.pone.0009357.g002
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ly. After intramuscular injection of glycerol on day 0, creatinine
levels increased to as high as 1.10 mg/dl, showing a peak between
48 and 72 hours after injection. Similarly, the level of BUN
increased up to 70 mg/dl after glycerol injection and a peak was
detected between 48 to 72 hours. The injected dose of glycerol
chosen is a sub-lethal dose. Therefore, after the peak, levels of
creatinine and BUN resolved back to normal after a period of 3
weeks.
Remarkably, animals subjected to damage induced with
glycerol and receiving an intrarenal hAFSC injection demonstrat-
ed no increase in the levels of creatinine or BUN during the
expected acute phase of injury, showing a statistically significant
difference when compared with animals treated with PBS after
ATN or with animals that underwent only ATN induction.
Absence of increases in both creatinine and BUN levels was
demonstrated also in animals that received only intra-renal
injection of hAFSC without glycerol damage, demonstrating that
hAFSC alone did not alter these kidney physiological parameters
over time (Figure 5A,B).
Morphological Studies
In Figure 6 is shown an example of PAS histological staining of
a typical animal treated with hAFSC after ATN induction,
compared with another typical animal that underwent only ATN
Figure 3. In vivo luciferase detection of hAFSC in ATN damaged kidneys. hAFSC transduced with luciferase maintain the expression of
luciferase under bioluminescence over many population doublings as demonstrated by the presence of optical signal after 20 passages in culture
(tube on right) when compared with hAFSC that were not transfected (tube on left) when stimulated with the substrate for luciferase (A). The lowest
number of cells that exhibit detectable luciferase signal in vitro is 16105. Luciferase gain range is shown on right (B). C. In vivo imaging showing
bioluminescent detection of hAFSC after injection into a damaged nu/nu mouse kidney over a period of 21 days. In panel 1 is shown a negative
control, injected only with luciferin, the luciferse substrate. The optical signal is strongly present during the first 5 hours post injection (panel 2–5),
decreases over time (panel 6–8), but is still present after 21 days (panel 9). In panel 10 is shown the bioluminescence gain range. D. RT-PCR
demonstrates the presence of the luciferase gene (expressed only by human transfected hAFSC clones) in 5 injected kidneys, compared with the cells
before injection (positive control) and in non-injected kidney (negative control). Human ACTB is used as housekeeping gene. E. Immuno-fluorescence
staining of injected kidney with hAFSC after 3 weeks. The red fluorescence (arrow) confirms the presence of hAFSC expressing luciferase. The nuclei
are stained with DAPI (206).
doi:10.1371/journal.pone.0009357.g003
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Figure 4. Integration and structural differentiation of hAFSC injected into glycerol induced damaged ATN kidneys. A. Frozen section
of a kidney injected with hAFSC after 1 week. The cells are evident as red fluorescence of the surface marker CM-DiI. The nuclei are stained with DAPI
(306). It is noticeable that CM-Dil-labelled-hAFSC locate in the proximity of tubular structures after 3 weeks following injection and are shown to
express Peanut Agglutinin (B) as well as Dolichus Biflorus Agglutinin (arrow) (C); hAFSC locate also in close proximity of the glomerular structures and
express human Glial Derived Neutrofic Factor (arrow) (D). The nuclei are stained with DAPI (406). E. Double Immuno-fluorescent staining of injected
kidney with luciferase transduced hAFSC (and not CM-Dil labeled), showing the same cells expressing both Aquaporin 2 and luciferase (arrow), 3
weeks after injection. The nuclei are, stained with DAPI. (306). F. RT-PCR performed on RNA isolated from kidney, 3 weeks after hAFSC injection. The
expressed kidney markers such as NPHS1, AQP2, PAX2, OCLN, identified by primers designed with human specific sequences. Human ACTB is used as a
housekeeping gene. G RT-PCR showing the specificity, as indicated by human sequences not cross-reacting with mouse.
doi:10.1371/journal.pone.0009357.g004
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(Figure 6A-C), both sampled during the expected peak of IM
glycerol induced ATN damage at 48–72 hours. In particular, in
Figure 6A–C an increase in the number of damaged tubules is
seen from 24 hours to 72 hours in the glycerol-treated control
animals. By 72 hours the damage appears to be more severe due to
cast formation (arrow, Figure 6C) within damaged tubules. In
Figure 6D-F it is shown that in glycerol-injected animals treated
with hAFSC, a number of damaged tubules is present at 48 hours,
but by 72 hours the number of damaged tubules and the cast
formation within them has decreased significantly. The evaluation
of tubular injury, based on counting cast formation in different
experimental groups at different time points (24 hours, 48 hours,
72 hours, 1 week and 2 weeks) showed that animals that were
treated with hAFSC exhibited less damage during the peak phase,
compared to the animals that were not treated with hAFSC, or to
those treated with saline vehicle solution (PBS). In addition,
animals that underwent only intrarenal injection of hAFSC did not
show any cast formation (Figure 6G).
Animals that did not undergo any treatment at all (normal
control animals) did not show any cast formation at basal level
(data not shown), and were therefore not included in the statistical
analysis comparing ATN groups of animals.
Figure 5. Protective effect of injected hAFSC as determined by measurements of blood creatinine and BUN levels. In these graphs the
difference in levels of blood creatinine (A) and BUN (B) between the experimental groups are shown (Blue: animals that underwent only ATN; Red:
animals that underwent ATN and intrarenal injection of PBS; Green: animals that underwent ATN and intrarenal injection of hAFSC; Orange: animals
that underwent intrarenal injection of hAFSC but not ATN; Black: control animals, no ATN and no injections), shown at different time points (24 hours,
48 hours, 72 hours, 1 week and 2 weeks). Values are presented as mean 6 SEM (* p,0,05; ** p,0,01).
doi:10.1371/journal.pone.0009357.g005
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Figure 6. Protective effect of injected hAFSC, determined by maintenance of the morphological structure in glycerol induced ATN
damaged kidneys. In these figures are shown the most representative PAS-Staining of kidney sections of mice treated only with injection of
glycerol over the course time of 24 hours (A), 48 hours (B) and 72 hours, (C) when compared with mice treated with injection of glycerol and hAFSC
at 24 hours (D), 48 hours (E) and 72 hours (F) after injection. In the mice treated only with glycerol the level of disruption of brush border (BB), the
desegregation of tubular membrane (DTM) and cast formation (CF) increased over time, while the injection of hAFSC preserved the morphology of
the tubular structures after they have been damaged following IM glycerol injection. The graph (G) represents the percentage of damaged tubules in
the different experimental groups. Blue: animals that underwent only ATN; Red: animals that underwent ATN and intrarenal injection of PBS; Green:
animals that underwent ATN and intrarenal injection of hAFSC; Orange: animals that underwent intrarenal injection of hAFSC but not ATN) at
different time points (24 hours, 48 hours, 72 hours, 1 weeks and 2 weeks) per total number of tubules in the sections. Values are presented as mean6
SEM (* p,0,05; ** p,0,01).
doi:10.1371/journal.pone.0009357.g006
Amniotic Stem Cells and Kidney
PLoS ONE | www.plosone.org 7 February 2010 | Volume 5 | Issue 2 | e9357
Proliferation (PCNA Staining) and Apoptosis (TUNEL
Staining)
The proliferative activity and the apoptosis of tubular cells were
compared between the experimental groups at the different time
points (24 hours, 48 hours, 72 hours, 1 week and 2 weeks).
The analysis of the data showed no statistical difference in
proliferation activity between the animals that were injected in the
kidney with saline vehicle solution (PBS) after glycerol injection
versus animals that underwent only glycerol injection over time. In
contrast, animals subjected to damage induced with glycerol and
that received intrarenal hAFSC injection demonstrated a signif-
icant increase in cell proliferation between 48 hours and 72 hours
(Figure 7A).
Apoptosis increased in animals that were injected with saline
vehicle solution (PBS) after glycerol injection as well as in animals
that underwent only glycerol injection, as measured during the
acute phase of injury. In contrast, in animals that received
intrarenal injection of hAFSC a decrease of apoptosis was noted,
as shown in Figure 7B. The absence of increase in proliferation
or apoptosis was demonstrated in animals that received only
intrarenal injection of hAFSC without glycerol damage, demon-
strating that hAFSC alone do not adversely influence normal
tubular cells (Figure 7A,B). Animals that did not undergo any
Figure 7. Protective effect of injected hAFSC as determined by increase of proliferation and decrease of apoptotic tubular cells in
glycerol induced ATN kidneys. In these graphs is shown the proliferation activity in tubular cells (A) and the apoptosis (B) between the
experimental groups (Blue: animals that underwent only ATN; Red: animals that underwent ATN and intrarenal injection of PBS; Green: animals that
underwent ATN and intrarenal injection of hAFSC; Orange: animals that underwent intrarenal injection of hAFSC but not ATN;) at different time points
(24 hours, 48 hours, 72 hours, 1 week and 2 weeks). Values are presented as mean 6 SEM (* p,0,05; ** p,0,01; *** p,0,001).
doi:10.1371/journal.pone.0009357.g007
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treatment (control animals) did not show any remarkable apoptosis
or proliferation (data not shown), and were therefore not included
in the statistical comparison between ATN groups.
Immuno-Cytokine Profile
Since the salutary effect of hAFSC injection occurred during the
acute phase of ATN, we postulated that this protective effect might
involve acute changes in the kidney’s cytokine expression.
Cytokines expression arrays were performed using Cytokine Array
Membranes (Figure 8A). For relative ease of interpretation, the
different cytokines are displayed as five broad functional clusters,
based on their principal immunological functions: 1. Interleukins;
2. Activators of B Lymphocytes; 3. Activators of Natural Killers;
4. Chemotactic attractors of Granulocytes and Macrophages; 5.
Multiple biological effectors. We did not include a specific
category for activators of T Lymphocytes, since in this mouse
model activated T Lymphocytes are not expressed. We analyzed
the expression of cytokines in all the experimental groups at
different time points up to two weeks. The mouse specific cytokine
assay does not cross react with the human cytokine assay. This was
confirmed by incubating digested kidney extracts with membranes
specific for human cytokines and conversely incubating hAFSC
with membranes specific for mouse cytokines (data not shown).
Mice treated with intrarenal hAFSC after induction of ATN
showed statistically significant comparisons, mostly at 7 and 14
days, in mouse cytokine levels, when compared with mice treated
with either intrarenal vehicle saline solution (PBS) or just with
ATN induction alone, or when compared with nu/nu mouse
kidney before any treatment, as shown in Table S1 and Table
S2 (Supplementary Data). There was no significant difference,
with very few exceptions, between the ATN mice treated with
vehicle solution (PBS) versus just ATN induction, as shown in
Table S2. In addition, the levels of cytokines in the hAFSC
treated ATN mice, compared with basal nu/numouse kidney levels
showed that there was an increase of anti-inflammatory cytokines
such as IL-10 and IL-1Ra (Table S1). Moreover, there was no
significant increase in pro inflammatory cytokines such as IL 27,
IL 12p70, IL 2, IL 23 (Table S1). Indeed the hAFSC injected
ATN mice showed a decrease in JE, M-CSF, MIP-2, MPC-5 and
KC expression, when versus the ATN mice treated with vehicle
solution (PBS) or just ATN induction (Figure 8B and Table S2).
Mice that were injected with hAFSC, only without inducing
ATN, underwent a limited tissue reaction in terms of production
of different cytokines, but for most of them this expression was very
early after the injection (within the first few days) and the levels
returned to normal by 14 days as shown in Table S1 and
Figure 8B. When the human cells are injected (both in mice with
or without ATN) there was a noticeable increase in human
cytokine levels, when compared with the cytokines expressed by
hAFSC before injection (in vitro culture) as reported in Table S3
especially during the first days after injection, while most of them
returned to normal at 7 days and were not detectable at 14 days.
Discussion
In this paper we demonstrate a protective role of hAFSC when
injected directly into nu/nu mouse kidneys with glycerol-induced
ATN. This model of ATN involves a complex sequence of events
wherein myoglobin, released from damaged muscle, damages the
epithelial cells of the proximal tubules, producing cast formation,
vasoconstriction and decreased glomerular filtration. Peak of the
damage represented by high levels of apoptotic cells, increased
levels of creatinine and BUN and by histological analysis was
confirmed to be between 48–72 after induction of ATN.
The ability for hAFSC to home to injured organs was confirmed
using luciferase positive hAFSC detected their bioluminescence
after injection. As shown in our previous paper [10] the amount of
hAFSC detected by bioluminescence in nu/nu mice, wherein the
acute injury was performed in the lung instead of the kidney,
decreased over time, showing a strong signal in the lung at the
beginning that fades over the next few days. Nevertheless herein
following intrarenal injection after ATN kidney damage, the
bioluminescent signal is still present in the kidney after 21 days and
hAFSC were found specifically located among the tubules. In
order to determine if the injected cells can differentiate into
tubular epithelial cells we performed both immunohistochemistry
and RT-PCR using human specific antibodies and human
primers. Genes such as PAX2, NPHS1 and lectins like Dolicholus
Biflorus and Peanut Agglutinin are expressed by injected cells,
indicating that at least some of the integrated cells are able to
commit toward renal differentiation. Furthermore, in some rare
instances, injected hAFSC cells could express human Glial
Derived Neurotrophic Factor (GDNF), which is expressed during
very early kidney development; GDNF is not usually detectable in
the adult kidney, indicating that injected hAFSC can express also
embryonic renal markers, retaining the ability of going through
the nephrogenesis. We have previously shown that hAFSC have
the potential to integrate into embryonic kidneys and can
participate in key steps of nephrogenesis, indicating that hAFSC
can be induced toward to a renal fate when placed in an
appropriate environment [11]. However, both in this study as well
as in this previous study, the efficiency of integration into kidney
lineages was not strikingly high and we did not detect significant
clonal expansion of integrated hAFSC. We, therefore, postulated
that perhaps another benefit could be afforded the injured kidney
than simply a structural one by the presence of hAFSC during the
acute phase of injury.
We determined that hAFSC have the ability to modulate kidney
function during ATN, as reflected in serum creatinine and BUN
levels. However, the timing of hAFSC is critical: hAFSC injected
during the acute phase of ATN (between 48–72 hours after the IM
injection of glycerol), had no effect on creatinine and BUN levels
(data not shown), and implies that if injury is already established
the damage is not attenuated. In contrast, hAFSC injected into the
kidney on the same day of glycerol injection resulted in no
observed peaks in creatinine or BUN. This beneficial effect with
hAFSC was also correlated with significant increases in prolifer-
ative activity of tubular epithelial cells, decreased cast formation,
and decreased apoptosis of tubular epithelial cells.
We therefore speculate that hAFSC can, when injected early
enough (in this study contemporaneously with the time of injury)
attenuate acute renal damage, underscoring the potential
protective effects of hAFSC. Moreover, even 14 days after injury
hAFSC injection into the kidney still correlated with increased
tubular cell proliferation and less tubular damage. Thus, we
hypothesize that hAFSC might accelerate the proliferation of
epithelial tubular cells that were only partially damaged, while in
addition preventing apoptosis. This mechanism of protection
therefore appears to lead to better maintenance of tubular
structure, as seen in PAS staining, thus avoiding the increase in
BUN and creatinine typically seen in IM-glycerol-induced ATN.
During acute renal injury the immune response plays a key role.
Damaged kidney endothelial cells attract leukocytes, vasomedia-
tors are released with injury, and epithelial cells of the tubule
produce pro-inflammatory and chemotactic cytokines [12].
Bonventre et al. [13] and Lin et al. [14] have shown recently that
the mechanism by which bone marrow stem cells contribute to
renal repair was by attenuating the immune response, rather than
Amniotic Stem Cells and Kidney
PLoS ONE | www.plosone.org 9 February 2010 | Volume 5 | Issue 2 | e9357
Figure 8. Immunomodulatory effects of hAFSC once injected into glycerol induced ATN-damaged kidneys. Mouse Cytokines were
analyzed among all the experimental groups to evaluate changes in the inflammatory milieu. A. Developed multiplex cytokine assay membranes for
mouse with ATN, mouse with ATN and Injection of PBS and Mouse with ATN and injection of hAFSC, showing the markedly different expression
patterns of cytokines at 14 days. B. Schematic outline representation of mouse cytokine expression over the 14 days among different groups: 1. Mice
with ATN only. As a general trend of cytokine expression, in these animals the pro-Inflammatory cytokines increased or remained highly expressed
and anti-inflammatory cytokines showed decreased or low expression; 2. Mice with ATN and injection of hAFSC. As a general trend of cytokine
expression, it is evident that the anti inflammatory cytokines increased over the 14 day study period, while pro-Inflammatory cytokines decreased; 3.
Mice with ATN and injection of PBS. As a general trend of cytokine expression, in these animals the pro-Inflammatory cytokines increased or remained
highly expressed and anti-inflammatory cytokines showed decreased or low expression; 4. Mice without ATN and injection of hAFSC. As a general
trend of cytokine expression, in these mice the anti-inflammatory cytokines are mildly increased over the 14 days, while pro-inflammatory cytokines
are not expressed or show decreased expression over the 14 days.
doi:10.1371/journal.pone.0009357.g008
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through integration or differentiation of the stem cells into the cells
of the damaged organ. They also speculated that the protection in
these animals was not through integration and differentiation of
the injected MSC, because of the very short period of time with
which a protective response was observed [15].
The animal model used in these experiments (Athymic Nude-
Foxn1nu) was chosen in order to be able inject human derived stem
cells and evaluate their effect over time, avoiding outright
rejection. Nu/nu mice are immunodeficient, lacking activated T
Lymphocytes but not their precursors. They have normal B
Lymphocytes and they have evidence of increase numbers of NK
cells. Thus, even though they are immunodeficient, they do possess
some ability to mount and modulate a partial immune response
when stimulated [16]. In addition to the animals that underwent
only ATN and mice with no treatment, we introduced mice that
were injected with a vehicle saline solution (PBS) after glycerol
damage and compared their respective cytokine levels. Therefore,
to further investigate the potential mechanisms by which hAFSC
enhance renal protection, we examined intrarenal cytokines, to
determine whether there is a general change in inflammatory
cytokine pattern in mice that were treated with hAFSC compared
to our controls. We decided to evaluate the immune response in a
time period extending up to two weeks, instead of only the first 3
days, because even if this is an acute injury model, the response of
nu/nu mice with glycerol induced ATN to human stem cells after
kidney injection has never been demonstrated before, and the
response could diverge significantly from wild type mice injected
with mouse-specific stem cells.
The kidneys of the ATN mice treated with hAFSC presented a
profile of mouse cytokines that indicated a lower expression of pro-
inflammatory molecules, as compared to mice treated with either
ATN plus PBS or that underwent only ATN, versus the basal level
in mice before any treatment. One possible explanation for this
result may be the increased presence of IL-10 and IL1Ra, both of
which are anti-inflammatory cytokines, in the mice treated with
hAFSC cells. Moreover, the presence of both of these two anti-
inflammatory interleukins appears to have stimulated the produc-
tion of IL-6, which also possess anti-inflammatory properties in the
presence of increased levels of IL-10 and IL1Ra [17]. In mice with
ATN and treated with PBS or only with ATN, there is no change
in expression of IL-10 and IL-6. Therefore we conclude that
inflammation can persist over a longer period of time in these non-
hAFSC treated mice. Furthermore, mice treated with hAFSC did
not show increased levels of important pro-inflammatory cyto-
kines, such as IL27, a Natural Killer cell attractor [18] or IL12p70,
which is known to be inhibited by IL-10 [19,20]. Furthermore, the
injection of the cells prevented an increase in SDF-1 (Stromal cell-
Derived Factor-1) a potent B chemoattractor, which is produced
by several cell types [21], thus indicating that many different
immune functions can be slowed down or controlled by injection
of hAFSC. Specific chemoattractants such as KC (Keratinocyte
Chemoattractant), JE/MCP-1 (Monocyte Chemoattractant Pro-
tein 1), MCP-5 (Monocyte Chemoattractant Protein 5) and MIP-2
(Macrophage Inflammatory Protein 2) are also diminished in mice
treated with hAFSC.
It is beyond the scope of the current study to define the specific
role of each individual cytokine involved in the immune response
in kidney injury and repair. Nevertheless, the total effect of the
cytokines and chemokines expressed in the ATN kidneys of mice
treated with hAFSC evidently lead to a combined action helping
to ameliorate the acute phase of injury.
It is also important to note that in ATN mice that were injected
with hAFSC, all cytokines (pro and anti-inflammatory) had
returned to normal by 14 days, particularly when compared with
ATN mice injected with PBS or with just ATN, i.e., in the latter
mice, inflammation persists longer. This is also in accordance with
the presence of tubular damage in the latter groups at 14 days.
This suggests that an important function of hAFSC may be to
actually prevent the acute injury. We further speculate that, in this
particular nu/nu model of ATN, the beneficial down-modulation
of the most important immune cytokines may actually be relatively
delayed, because nu/nu mice, lacking activated T lymphocytes, can
induce alternative pathways of immune responses. One great
practical advantage of studying the impact of hAFSC in the nu/nu
model of ATN is that we could measure and compare the
cytokines expressed by the human cells versus those the recipient
mouse kidney. Interestingly, human cytokine levels (compared
with the basal level secreted in the hAFSC supernatant in vitro
before injection) are significantly increased early in the course of
ATN (as shown Table S3), while the mouse cytokines are only
significantly increased after 1 or 2 weeks. Thus the human cells are
able to produce cytokines that can modulate the nu/nu mouse
response to ATN.
With a few exceptions, most human cytokines are also active on
mouse cells [22–27], so both the combined effects of human and
mouse cytokines may have affected the kidney inflammation and
tissue homeostasis milieu. We think that this may be an important
concept, and therefore consider that maybe cytokines derived from
both the injected hAFSC and the endogenous mouse cytokines are
responsible for the observed protective effects. In addition, it is
relevant to underline the decrease in number of injected hAFSC
found in the kidney over time, as shown both by the
bioluminescence images and by the immunohistochemistry data,
as well as by the absence of human cytokine expression at 14 days.
What is essential to underline in this work and in this mouse model
of ATN is that, in nu/nu mice treated with hAFSC, there is over all
improvement in the maintenance of tissue homeostasis, which
prevented progression of the acute phase in glycerol-induced
ATN, most likely through stimulating proliferation of tubular
epithelial cells and by cytokine-mediated paracrine mechanisms.
Furthermore, after the acute phase, the decrease of creatinine
levels, as well as less cast formation and the increase of tubular cell
proliferation is still statistically significant at two weeks, at which
time damage still persists in the ATN mice treated only with PBS
or not treated at all. This is also in accordance with the data on
cytokine levels that are still significantly elevated at 1 and 2 weeks
in ATN mice treated with PBS only or not treated at all, as
compared to ATN mice treated with hAFSC in which cytokine
levels had resolved by 1–2 weeks.
To rule out whether hAFSC alone can cause damage to the
kidney and/or produce cytokines once injected in vivo, we injected
them into nu/nu mice without ATN induction. In these mice,
injected only with hAFSC there was no alteration of creatinine or
BUN, no increase in apoptosis or proliferation or tubular damage;
thus indicating that hAFSC per se do not alter the normal
physiology and morphology of the kidney. However injection of
hAFSC alone did stimulate the production of some cytokines by
nu/nu mouse kidney, but their levels were relatively low and only
detectable predominantly during the first few time points, and
rapidly resolved back to normal before 14 days, as compared with
ATN mice injected with PBS. In addition, in these mice, there was
an increase of levels in IL-10 and IL-1Ra and IL-6 following
hAFSC injection (similar to that noted in the mice injected with
hAFSC following ATN), there was no increase in SDF-1 and also
they expressed lower levels of NK attractors as well as macrophage
attractors. Thus, hAFSC do stimulate a modest tissue reaction by
nu/nu mice, but this did not cause any measurable perturbation of
kidney function. In addition, the human cytokines produced by the
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injected cells in mice that did not undergo ATN disappear quickly
and with no apparent adverse consequences.
In conclusion, we have demonstrated that early direct injection
of hAFSC into the kidney strongly ameliorates ATN injury, as
reflected by more rapid resolution of tubular structural damage, by
tubular cell proliferation and by normalized creatinine and BUN
levels. In addition, our data show evidence of potent immuno-
modulatory effects of hAFSC that appear to control the local
immune response in favor of a tissue cytokine and cellular milieu
that promotes prevention or resolution of tissue damage. Taken
together these findings suggest that hAFSC may have therapeutic
potential in ATN and, by extrapolation, perhaps in other kidney
diseases.
Materials and Methods
Isolation and Labelling of hAFSC
Samples of human amniotic fluid from male fetuses (12–18 week
of gestation) were provided to our laboratory by Genzyme
Genetics Corporation (Mongovria, CA, USA) after karyotyping
analysis. No written or verbal consent was required since samples
were not identified and information obtained about the samples
was limited to karyotype and fetal health status. The stem cell
population was separated from the general human amniotic
cellular milieu using standard Magnetic Sorting (MACS) tech-
niques [Miltenyi Biotech] against the cell surface marker, c-kit, as
described by Atala et al. [9]. Pluripotential characteristics of the
clonal and subclonal groups were tested according to protocols
also outlined by Atala et al. [9]. The isolation and characterization
of pluripotency of human and mouse AFSC is a very well
established protocol in our laboratory, and clones used in these
experiments are the same as used for our previous publications
[10,11]. Expression of pluripotent markers such us Oct-4, stage-
specific-embryonic antigen 4 (SSEA-4), CD90 and CD105 were
confirmed using FACS (data not shown) in order to confirm their
phenotype described in the original paper [9]. Clones, derived
from a single sample of human amniotic fluid, were then cultured
in petri dishes in medium containing a-MEM Medium [Gibco/
BRL] supplemented with 20% Chang Medium B [Irvine
Scientific] and 2% Chang Medium C [Irvine Scientific], 20%
Fetal Bovine Serum [Gibco/BRL], 1% L-Glutamine [Gibco/
BRL], and 1% antibiotics (pen-strep) [Gibco/BRL]. hAFSC, used
for in vivo injection, were rekaryotyped at passage 38 using
standard protocols by the Core Laboratory of Clinical Cytoge-
netics directed by Dr Wu at Childrens Hospital Los Angeles.
Before injection, a clonal hAFSC population at passage 40 was
trypsinized in 0.05M trypsin/EDTA [Gibco/BRL] solution and
centrifuged at 1500 rpm for 5 min, and then labeled with a cell
surface marker CM-DiI [Molecular Probe] following the manu-
facturer’s instructions, in order to track the cells after injection.
Briefly, the cells were incubated with a working solution of 1 mg/
ml of CM-Dil for 5 minutes at 37uC followed by an incubation of
15 minutes at 4uC and then three washes with phosphate-buffered
saline (PBS) [Gibco/BRL].
ATN Induction and Injection of hAFSC
Rhabdomyolysis-related ATN was induced in female nu/nu
mice [Jackson Laboratories] by intramuscular injection with 50%
hypertonic glycerol solution in water (10 ml/kg body/wt) [Sigma-
Aldrich] following deprivation of water for 22 hours. Controlled
intramuscular injection of glycerol was performed under anesthe-
sia by surgically exposing the caudal thigh muscle and slowly
injecting the glycerol solution prior to delivery of cells. In nu/nu
mice the amount of glycerol required for induction of ATN was
50% higher than the dose needed in wild type mice (data not
shown). This suggests that the T-deficient mice are relatively
protected as compared to wild type mice against glycerol-
rhabdomyolysis-induced ATN [28].
Animal experiments were performed in adherence to the
National Institutes of Health Guide for the Care and Use of
Laboratory Animals, with institutional Animal Care and Use
Committee approval. The mice were carefully anesthetized using
isofluorane inhalation. Once satisfactory anesthesia was achieved,
the mice were prepared for surgery using chlorhexidine. A 1 cm
dorsal incision was made, both kidneys were carefully delivered via
the incision, and the labeled hAFSC (16106 resuspended in 50 ml of
saline vehicle solution, PBS) at passage 40 were carefully injected
into the renal cortex of both kidneys with a 30–33 gauge needle,
using a microinjector Eppendorf TransferMan NK2 Injector
[Eppendorf], 2 hours after intramuscular glycerol injection. The
kidneys were then replaced into the retroperitoneum, the incision
closed with polypropylene suture and the mice were allowed to
recover from anesthesia. The animals were maintained on a heating
pad throughout the period of anesthesia. 0.1 mg/kg of buprenor-
phine was administered subcutaneously and 1 mg/kg bupivicaine (a
local anesthetic) along the incision margins just prior to wound
closure to provide post-operative pain relief. The animals were
sterilely draped to prevent contact of the kidneys with the skin of the
animal to reduce risk of peritonitis. As control, mice were injected
with saline vehicle solution (PBS) 2 hours after glycerol damage. In
addition, another animal group was injected only with hAFSC
without previous glycerol damage using the same technique
described above for the cell suspension and surgery.
Tissue Processing
At different times points (from 24 hours to 3 weeks), the injected
and the control mice were sacrificed. The kidneys were extracted,
washed in PBS, and processed in one of the following ways
depending on the analysis performed.
1. RNA/DNA extraction. The kidneys were minced in small
pieces and the RNA extracted using Qiagen RNeasy kit [Qiagen]
according to the manufacturer’s instructions. Total RNA was
isolated using the RNeasy Mini Kit [Invitrogen] as described on
the data sheet. Briefly, with the use of silica-gel columns RNA is
separated from DNA through centrifugation after lysis and
homogenization of the samples. Ethanol addition allows RNA to
bind the silica-gel before the centrifugation step. The RNA
solution obtained was then processed with DNAse treatment
[DNAse I, Invitrogen] to avoid any possible genomic
contamination. 1 mg of total RNA was reverse transcribed using
SuperScript II reverse transcriptase [Invitrogen]. Amplification of
the resulting cDNA was carried out using only specific human
primers not coding for mouse sequences. A PCR thermal cycler
[Eppendorf] was employed after an initial denaturation step at
95uC for 10 minutes. We used a denaturation step at 95uC for 30
seconds, an annealing step at the temperature specific for each
primer (ranging from 54uC to 60uC) for 45 seconds, and an
extension step at 72uC for 45 seconds for a total of 35 cycles.
Detection of the PCR amplification products was performed by
size fractionation on 1% agarose gel electrophoresis. As a
housekeeping gene, amplification of fragments of the human b-
actin RNA was performed. Specific human primer sequences,
predicted sizes of amplicons and specific annealing temperatures
are shown in Table 1.
In order to perform PCR on the genomic DNA to evaluate the
presence of the luciferase gene, DNA extraction was performed
following standard protocols of the Qiagen DNeasy kit [Qiagen,].
Briefly, the kidney was cut in small pieces and incubated at 55uC
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with proteinase K until completely lysed. To the mixture was then
added buffer AL and ethanol 70% furnished by the kit to obtain
ideal DNA binding conditions to the DNeasy Mini Spin column.
After centrifugation and washing steps DNA was collected and
PCR was performed as previously described.
2. Histology. Kidneys were fixed in 4% paraformalde-
hyde[Sigma-Aldrich] in PBS for 8 hours at 4uC, dehydrated
through a gradual series of alcohol, embedded in paraffin, and
sectioned at 4–5 mm. The sections were deparaffinized for 15
minutes in histochoice [Sigma-Aldrich], 5 minutes in 100%
alcohol, 5 minutes in 95% alcohol, 5 minutes in 70% alcohol; 5
minutes in 50% alcohol, 5 minutes in 30% alcohol and then water.
The sections were then stained with Periodic Acid Schiff (PAS)
[Sigma-Aldrich] to evaluate kidney morphology. The slides were
immersed in Periodic Acid Solution [Sigma-Aldrich] for 5 minutes
at room temperature; rinsed in several changes of distilled water,
then stained with Schiffs reagent [Sigma-Aldrich] for 15 minutes
at room temperature, washed in running tap water for 5 minutes
and finally counterstained with hematoxylin solution Gill [Sigma-
Aldrich] for 90 seconds. In the end the slides were rinsed in
running tap water, dehydrated, cleared and mounted in mounting
medium PROTOCOL XYLENE BASED [Fisher Scientific].
In addition, some kidneys were frozen in liquid nitrogen using
Tissue-Tek O.C.T. compound [Finetek] and stored at 220uC.
When required, kidneys were cryosectioned at 5 mm and then used
for immuno-histochemistry.
Transduction of the AFSC with Luciferase Gene:
Bioluminescent Detection
Clones of hAFSC were transduced with a lentiviral vector
(SMPU-R-MNCU3-LUC based on HIV-1 that transduces the
firefly luciferase gene) made by the Vector Core Facility at
Childrens Hospital Los Angeles following standard protocols as
reported in the paper by Crooks et al [29]. The Vector Core
performed the transduction, the titration of the virus and the
multiplicity of infection. Briefly, two cycles of transduction were
performed by removing old medium and adding new virus
supernatant and medium. 24 hours after the initial transduction,
cells were thoroughly washed 3 times with PBS before
transplantation or in vitro analysis. The percentage of the
transfected cells was 40%; positive clones were selected and used
for the experiments. Before in vivo injections, a simple in vitro test
was employed to determine the minimum amount of hAFSC
detectable by bioluminescence. Different concentrations of the
cells ranging from 56104 to 26106 were evaluated. In addition,
the expression of the luciferase gene was confirmed by PCR after
20 passages in culture. A number of 25 animals, 10-week old nu/
nu mice, obtained from Jackson Laboratories were injected
directly into the kidney with luciferase-transduced hAFSC
(16106 cells/mouse diluted in 50 ml ofPBS) after glycerol
damage. In vivo optical imaging was performed with a prototype
IVIS 3-dimensional bioluminescence/fluorescence optical imag-
ing system [IVIS 100, Caliper Life Sciences, Hopkinton] at
different time points.
Prior to imaging, each mouse was given an intraperitoneal
injection of luciferin [Promega] at a dose of 125 mg/kg, as
previously described [29]. As control, to exclude background
signal, 5 mice were injected only with luciferin and no cells.
General anesthesia was then induced with 5% isoflurane and the
mouse was placed in the light-tight heated chamber; anesthesia
was continued during the procedure with 1% isoflurane
introduced via a nose cone. The imaging system consists of a
Table 1. List of the human primers, the size of the products and the annealing temperature used in the experiments.
Gene Primer Sequenze (59R39) Size (bp) Annealing Temperature
Nephrin, NPHS1 aca cgg agc aca cat acc ac
gga ttg gag agg agc aga ag
570 59
Zona Occludens-1, ZO1 agg aga ggt gtt ccg tgt tg
gct ggt ttt gct gtt gtt ga
760 59
Glial Derived Neurotrophic Factor GDNF tat ggg atg tcg tgg ctg t
aca cct ttt agc gga atg ctt
630 58
Aquaporin-1, AQP1 cac ctc ctc cct gac tgg
ggt tgc tga agt tgt gtg tga
290 58
Aquaporin-2, AQP2 gat cac gcc agc aga cat c
ggg cag gat tca tag agc ag
240 59
Tam-Horsfall-Protein, THP tag acg agg act gca aat cg
gtc ccg gtt gtc tct gtc at
220 59
OB-Cadherin, CDHOB Cactgtctttgcagcagaaatc
tacaatgaccaaggagaatgacg
430 55
CD24 acc cag cat cct gct aga c
ctt aag agt aga gat gca gaa
290 59
LIM1, LIMX1 aag agc gag gat gaa gat gc
tca gga ggc gaa gtagga ac
620 59
Occludin, OCLN gcc ctc gca acc caa att tta
tca ttc act ttg cca ttg ga
430 58
PAX-2, PAX2 aac gac aga acc cga cta tgt t
agg atg gag gga cca act gc
740 59
Beta-actin, ACTB aga aaa tct ggc acc aca cc
ctc ctt aat gtc acg cac ga
390 55
Luciferase agg agc ctt cag gat tac aag att caa agt
gta ctt aat ca gaga ctt cag gcg ggt caa c
500 58
doi:10.1371/journal.pone.0009357.t001
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cooled, back-thinned charge-coupled device (CCD) camera to
capture both a visible light photograph of the animal taken with
light-emitting diodes and a luminescent image. A rotating mirror
and translatable animal stage allowed for images to be acquired
over 360u.
Immunostaining
Frozen and paraffin slides were stained for immunofluores-
cence. Paraffin slides were deparaffinized as previously described
while the frozen slides were fixed for 5 minutes in 80% methanol.
The slides were placed in 1% Triton x-100 [VWR] in PBS for 5
minutes (if the antigen was nuclear) and briefly washed in PBS.
The slides were then placed in working solution of Vector Antigen
Retrieval as described in the data sheet. [Vector Laboratories] for
three cycles at high power for 4 minutes each afterwards cooled
down at room temperature. After Avidin/Biotin blocking using the
Blocking Avidin/Biotin Vector kit [Vector Laboratories] for 30
minutes at room temperature, a second block was carried out for
30 minutes using 5% of Bovine Serum Albumin [BSA, Sigma-
Aldrich] diluted in PBS at room temperature. The slides were then
incubated in primary antibody at different concentrations in
solution a of 5% of BSA in PBS [Dolicholus Biflorus (conc. 1:50)
and Peanut Agglutinin (conc. 1:50) form Vector Laboratories,
Luciferase from Promega (conc. 1:100) and Glial Derived
Neurotrophic Factor (conc. 1:50) and Aquaporin 2 (conc. 1:50),
Santa Cruz] solution for one hour at room temperature
(Dolicholus Biflorus and Peanut Agglutinin) or overnight at 4uC
(Luciferase and GDNF). Afterwards, the slides were washed in
PBS for 5 minutes for 3 times. Secondary antibodies [Vector
Laboratories] were diluted 1:200 in 5% BSA in PBS – slides were
incubated in this solution for 1.5 hours at room temperature,
followed by washes in PBS for 5 minutes for 3 times. The
appropriate fluorescent marker [Texas Red or Fluorescein Avidin
DCS from Vector Laboratories] was then applied in a concen-
tration of 1:500 in PBS buffer for 5–10 minutes, followed by a final
wash in PBS for 5 minutes for 3 times. Sections were
counterstained with 49,6-diamidino-2-phenylindole (DAPI) (Vec-
tor Laboratories).
A Leica DM RA fluorescent microscope was used in
conjunction with Open Lab 3.1.5 software to image the staining.
Apoptosis and Proliferation Measurements
The number apoptotic cells were determined using the TUNEL
Apoptosis Detection Kit for paraffin-embedded tissue sections
(Biotin-labeled POD; GenScript c# L00297) at 24 hours, 48
hours, 72 hours, 1 week and 2 weeks after injections in every
experimental group (1. 10 control animals, no damage and no
treatment; 2. 10 animals that underwent only ATN; 3. 10 animals
that underwent ATN and intrarenal injection of hAFSC; 4. 10
animals that underwent ATN and intrarenal injection of saline
vehicle solution (PBS). 5. 10 animals that underwent intrarenal
injection of hAFSC but not ATN) as suggested by the kit data
sheet. All the reagents were furnished by the kit. Briefly, after
deparaffination and rehydration, the slides were incubated with
Proteinase K solution for 30 minutes at 37uC, washed in PBS for 2
minutes, and after blocking incubated with a TUNEL Reaction
Mixture for 1 hour at 37uC, followed by the Streptavidin –HRP
solution for 30 minutes at 37uC and finally revealed with the DAB
Substrate. If the staining was performed in frozen section the
fluorescent TUNEL [In Situ Cell Death Detection kit, fluorescein;
Roche, Applied-Science, c# 11684795910] was used. Briefly, the
cells were incubated at 37uC for one hour with the TUNEL
reagent and then washed in PBS. Slides were mounted with
Vector DAPI mounting medium [Vector Laboratories].
In all the experimental groups, the apoptotic nuclei were
counted as a fraction of the total number of nuclei present in the
section using consecutive, non-overlapping fields of TUNEL-
stained specimens. The percentage of apoptotic cells was estimated
without knowledge of the experimental group.
The number of proliferative cells was determined using the
PCNA Staining Kit (Invitrogen, c# 93–1143) at 24 hours, 48 hours,
72 hours, 1 week and 2 weeks after injections in every experimental
group above described as suggested by the kit data sheet. Briefly,
after deparaffination and rehydration and blocking, the slides were
incubated with a biotinylated mouse anti-PCNA primary antibody
for 1 hour at room temperature followed with incubation with
Streptevidin-HRP and revealed with DAB substrate. In all the
experimental groups the proliferative nuclei were counted as a
fraction of the total number of nuclei present in the section using
consecutive, non-overlapping fields of PCNA-stained specimens.
The percentage of proliferative cells was estimated without
knowledge of the experimental group.
Blood Collection, Creatinine and BUN Measurements
The facial vein was lanced with a 5 mm animal lancet and
blood collected using standard protocols approved by the
Animal Core Facility at Childrens Hospital of Los Angeles
and Saban Research Institute. Animals were divided into
different groups per each time point as follow (24 hours, 48
hours, 72 hours, 1 week and 2 weeks): 1. 10 animals for
measuring baseline creatinine and BUN levels; 2. 10 animals
that underwent only ATN; 3. 10 animals that underwent ATN
and intrarenal injection of hAFSC; 4. 10 animals that
underwent ATN and intrarenal injection of saline vehicle
solution (PBS). 5. 10 animals that underwent intrarenal
injection of hAFSC but not ATN.
The blood samples (30 mL) were collected into plasma
separation tubes with lithium heparin. They were centrifuged
at 13,000-RPM for 3 minutes and the plasma (upper layer) was
removed and stored at 280uC until analysis. A maximum of
15% of circulating blood was sampled in a given 14-day period
(total blood volume ,0.6% of total body weight). Post-damage
measurements were obtained every 24 hours. The blood
samples were used to monitor renal function, by analyzing
creatinine and BUN levels. Expression levels were determined
by a quantitative colorimetric assay [BioAssay Systems Cat #
DUCT-500 for creatinine Cat # DIUR-500 for BUN], using
an improved Jaffe method for creatinine, and an improved
Jung method for BUN without any pretreatment of the
samples.
Morphological Studies
Paraffin embedded kidney sections were prepared at 4 mm
thickness by a routine procedure and stained with PAS reagents
as described above. The kidney sections were divided as follow:
1. Sections obtained from mice that underwent ATN with no
injection of hAFSC sacrificed at 24 hours, 48 hours, 72 hours, 1
week and 2 weeks; 2. Section obtained from mice that underwent
ATN and injection of hAFSC sacrificed at 24 hours, 48 hours, 72
hours, 1 week and 2 weeks; 3. Sections obtained from mice that
underwent ATN with and injection of PBS sacrificed at 24 hours,
48 hours, 72 hours, 1 week and 2 weeks; 4. Sections obtained
from mice that underwent only intrarenal injection of hAFSC
and sacrificed at 24 hours, 48 hours, 72 hours, 1 week and 2
weeks. Tubular injury was evaluated based on different
parameters using PAS staining: including disruption of tubular
membranes and brush borders, but mainly relaying on cast
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formation since it is the most evident sign of damage in stained
sections.
In the experimental groups, the tubular injury was counted as a
fraction of the total number of tubules present in the section using
consecutive, non-overlapping fields of PAS-stained specimens. The
percentage of damaged tubules was estimated without knowledge
of the experimental group.
Cytokine Analysis
To examine if the injection of hAFSC would interfere with the
modulation of inflammation after acute kidney injury human and
mouse cytokines levels were measured in digested mouse kidneys at
24 hours, 48 hours, 72 hours, 1 week and 2 weeks in every
experimental groups (1. control animals, no damage and no
treatment; 2. animals that underwent only ATN; 3. animals that
underwent ATN and intrarenal injection of hAFSC; 4. animals that
underwent ATN and intrarenal injection of saline vehicle solution
(PBS). 5. animals that underwent intrarenal injection of hAFSC but
not ATN) using a multiple cytokine array technique Proteome
Profiler Array Kit, for human c# ARY005 and for mouse c#
ARY006, as suggested from the protocol [R&D Systems].
Kidneys are briefly washed in PBS, cut in pieces and added to
1 ml Phosphatase Inhibitor solution [ActiveMotif] and then
mechanically homogenized on ice for 1 minute, then 10 ml of
Triton X-100 [Sigma-Aldrich] is added before vortexing for 1
minute. The lysate is frozen at -80uC and thawed at room
temperature. The sample is centrifuged at 10.000 rpm for 20
minutes at 4uC. The supernatant is then transferred to a clean tube
and the protein concentration measured by UV-vis spectroscopy.
An equal amount of protein (300 mg) for the samples derived form
the different experimental groups (for hAFSC cultured in vitro to
test the basal level of cytokines expression before in vivo injection,
the amount of protein was extracted from 16106 cells, the same
amount used for injection) was incubated for one hour at room
temperature with a cytokine cocktail and each sample was then
added to the membrane and incubated overnight at 4uC. The
following day after several washing steps in Washing Buffer the
membranes were incubated with a streptavidin-HRP secondary as
suggested by the manufacturer (concentration 1:2000) for 30
minutes at room temperature. After washing in Washing buffer, it
was added the Super Signal West Pico Chemiluminescent
Substrate was added [ThermoScientific] to detect the signal. After
1 minute incubation the membranes were exposed for 20 seconds
to x-ray film. The signal was measured by counting the pixel
density and the data were analyzed using the Array Vision
Program [R&D Systems].
Statistical Analysis
All graphical data are displayed as the mean + SEM for n
animals in the number of independent experiments. For cytokines
one-way analysis of variance (ANOVA) with Bonferroni post-test
correction was used, and for all other data Mann-Whitney U test
was applied to compare two ore more (ANOVA) independent sets
of data. A P value less than 0.05 was considered statistically
significant.
Supporting Information
Table S1 In the table are reported the P values for the cytokine
analysis at 1,2, 3, 7 and 14 days. Column 1: Cytokines are grouped
by target and/or effects. Column 2: Mice with ATN and injection of
hAFSC versus normal nu/nu mouse (cytokine basal levels before
any treatment). Column 3: Mice with ATN and injection of PBS
versus normal nu/nu mouse (cytokines basal levels before any
treatment). Column 4: Mice with ATN only versus normal nu/nu
mouse (cytokines basal levels before any treatment). Column 5:
Mice with no ATN and injection of hAFSC versus normal nu/nu
mouse (cytokines basal level before any treatment). P values are
expressed as follows: * P,0.05; ** P, 0.01; *** P, 0.001 and they
represent the deviation from the control (normal nu/nu mouse); X:
increase of cytokine levels in the experimental groups compared to
the control; Y: decrease of cytokine levels in the experimental groups
compared to the control. Blank cells in the table indicate no
statistically significant change in cytokine expression.
Found at: doi:10.1371/journal.pone.0009357.s001 (0.08 MB
DOC)
Table S2 In the table are reported the P values for the mouse
cytokine analysis at 1, 2, 3, 7 and 14 days. Column 1: Cytokines
are grouped by target and/or effects. Column 2: Mice with ATN
and injection of hAFSC versus mice with ATN and injection of
PBS (X: increase of cytokine levels in mice with ATN and injection
of hAFSC versus mice with ATN and injection of PBS; Y: decrease
of cytokine levels in mice with ATN and injection of hAFSC versus
mice with ATN and injection of PBS). Column 3: Mice with ATN
and injection of hAFSC versus mice with ATN only (X: increase of
cytokine levels in mice with ATN and injection of hAFSC versus
mice with ATN only; Y: decrease of cytokine levels in mice with
ATN and injection of hAFSC versus mice with ATN only).
Column 4: Mice with ATN and injection of PBS versus mice with
ATN only (X: increase of cytokine levels in mice with ATN and
injection of PBS versus mice with ATN only; Y: decrease of
cytokine levels in mice with ATN and injection of PBS versus mice
with ATN only). P values are expressed as follows: * P, 0.05, ** P
, 0.01, *** P, 0.001. Blank cells in the table indicate no
statistically significant change in cytokine expression.
Found at: doi:10.1371/journal.pone.0009357.s002 (0.08 MB
DOC)
Table S3 In the table are reported the P values for the human
cytokine analysis at 1, 2, 3, 7 and 14 days. Column 1: Cytokines
are grouped by target and/or effects. Column 2: Mice with ATN
and injection of hAFSC versus hAFSC in vitro (hAFSC cytokines
basal level) (X: increase of human cytokine levels in mice with ATN
and injection of hAFSC versus hAFSC in vitro; Y: decrease of
cytokine levels in mice with ATN and injection of hAFSC versus
hAFSC in vitro). Column 3: Mice without ATN and injection of
hAFSC versus hAFSC in vitro (hAFSC cytokines basal level) (X:
increase of human cytokine levels in mice without ATN and
injection of hAFSC versus hAFSC in vitro; Y: decrease of cytokine
levels in mice without ATN and injection of hAFSC versus hAFSC
in vitro). P values are expressed as follows: * P, 0.05, ** P, 0.01,
*** P, 0.001. Blank cells in the table indicate no statistically
significant change in cytokine expression.
Found at: doi:10.1371/journal.pone.0009357.s003 (0.06 MB
DOC)
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